NewsAI-assisted

Thermo Fisher is taking measures to cope with plasmid DNA demand fluctuations

Thermo Fisher Scientific faces fluctuating demand, leading to layoffs of 74 employees at its plasmid DNA facility in California.

Mrudula Kulkarni
By Mrudula Kulkarni
Managing Editor - Pharma Now
Jun 6, 2024Updated Jun 26, 2025 · 2 min read
Thermo Fisher is taking measures to cope with plasmid DNA demand fluctuations
AI-assisted reporting
Reviewed by Mrudula Kulkarni, Managing Editor - Pharma Now

Thermo Fisher will lay off its 74 employees by 31st May 2024 at its Plasmid Manufacturing Facility in California. 



Thermo Fisher Scientific is a global leader in scientific solutions and boasts an impressive annual revenue of over $40 billion. Its extensive portfolio encompasses a spectrum of cutting-edge technologies and services seamlessly integrated under renowned brands like Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. This combination offers its customers unparalleled access to innovative solutions, streamlined procurement processes, and exceptional pharmaceutical services.


Thanks to its dedicated global team that keeps Thermo Fisher at the forefront of scientific innovation. 

However, as per the reports, Thermo Fisher Scientific shall lay off its 74 employees working in the plasmid DNA manufacturing facility in Carlsbad, California. According to the reports, the fluctuation in demand is why Thermo Fisher took such a measure. This adjustment in staffing levels will result in job reductions across the plasmid business, affecting 74 employees. The separation process is scheduled for May 31, 2024, per the Worker Adjustment and Retraining Notification (WARN) Act report submitted to California.

Despite these workforce adjustments, Thermo Fisher is committed to supporting its affected employees by providing job transition assistance during this transition period.

The future trajectory of the plasmid manufacturing lab is yet to be determined as Thermo Fisher continues to assess its options.


TopicsNews
Mrudula Kulkarni
Written by
Mrudula Kulkarni
Managing Editor - Pharma Now

My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.



Discussion

Loading discussion…

More from Pharma News

All stories →